Alliancebernstein L.P. Purchases 1,287 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Alliancebernstein L.P. grew its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 6.0% during the 4th quarter, HoldingsChannel reports. The firm owned 22,584 shares of the medical instruments supplier’s stock after acquiring an additional 1,287 shares during the quarter. Alliancebernstein L.P.’s holdings in LeMaitre Vascular were worth $2,081,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. Raymond James Financial Inc. acquired a new stake in LeMaitre Vascular in the 4th quarter valued at approximately $14,900,000. Segall Bryant & Hamill LLC bought a new stake in shares of LeMaitre Vascular in the fourth quarter valued at approximately $5,446,000. JPMorgan Chase & Co. grew its stake in shares of LeMaitre Vascular by 45.9% in the fourth quarter. JPMorgan Chase & Co. now owns 147,489 shares of the medical instruments supplier’s stock worth $13,590,000 after acquiring an additional 46,430 shares during the last quarter. Barclays PLC increased its position in LeMaitre Vascular by 394.5% during the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock worth $3,396,000 after acquiring an additional 29,180 shares during the period. Finally, State Street Corp raised its stake in LeMaitre Vascular by 3.6% during the 3rd quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier’s stock valued at $76,363,000 after purchasing an additional 28,525 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

LMAT has been the topic of a number of recent research reports. Wells Fargo & Company initiated coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price on the stock. Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Oppenheimer downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Finally, Lake Street Capital raised their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Five analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $95.25.

LeMaitre Vascular Stock Performance

LMAT opened at $84.67 on Thursday. LeMaitre Vascular, Inc. has a twelve month low of $62.39 and a twelve month high of $109.58. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of 46.27, a PEG ratio of 2.22 and a beta of 0.89. The firm’s 50-day simple moving average is $88.31 and its 200-day simple moving average is $93.56.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, hitting the consensus estimate of $0.49. The company had revenue of $55.81 million during the quarter, compared to analyst estimates of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. As a group, sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th were paid a $0.20 dividend. The ex-dividend date of this dividend was Thursday, March 13th. This represents a $0.80 dividend on an annualized basis and a yield of 0.94%. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s payout ratio is currently 41.24%.

Insider Transactions at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,009 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the transaction, the insider now directly owns 5,564 shares in the company, valued at approximately $456,915.68. This represents a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 10.79% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.